期刊
FUTURE ONCOLOGY
卷 15, 期 5, 页码 507-516出版社
FUTURE MEDICINE LTD
DOI: 10.2217/fon-2018-0677
关键词
inflammatory breast cancer; prognosis; SEER; subtype; survival; treatment
类别
资金
- Natural Science Foundation of China [81872459, 81803050]
- Social Science and Technology Development Major Project of Dongguan [2018507150241630]
- Natural Science Foundation of Guangdong Province [2018A030313666]
- Science and Technology Planning Projects of Xiamen Science and Technology Bureau [3502Z20174070]
Aim: To assess the outcomes of breast cancer subtype in inflammatory breast cancer (IBC). Methods: We retrospectively assessed IBC patients from the SEER program. Results: We identified 626 patients, including 230 (36.7%),100 (17.6%), 113 (18.1%), and 173 (27.6%) patients with HoR+/HER2-, HoR+/HER2+, HoR-/HER2+, and HoR-/HER2- subtype disease, respectively. Multivariate analysis demonstrated that, using HoR+/HER2- subtype as reference, patients with HoR+/HER2+ subtype had better breast cancer-specific survival (BCSS) and overall survival (OS), and patients with HoR-/HER2- subtype had worse BCSS and OS, while BCSS and OS were comparable for HoR-/HER2+ subtype. Similar trends were observed in patients who received surgery, radiotherapy, chemotherapy or trimodality therapy. Conclusion: Breast cancer subtype is clinically useful for predicting survival outcome in IBC. The HoR+/HER2- subtype shows poorer survival outcome than HoR+/HER2+ subtype.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据